Analysis of Serum of Patients With Alzheimer’s Disease for the Level of Advanced Glycation End Products

Abstract

Data on the serum level of advanced glycation end products (AGEs) in Alzheimer’s disease (AD) patients are scarce, although a specific biochemical marker easy to detect in body fluids is desired for an early diagnosis of disease and to monitor the effects of therapeutic treatment. In the current study, the content of AGEs was examined with an immunochemical assay in the sera of AD patients, in the frame of a search for a biochemical marker of disease. Subjects with AD and vascular dementia (VaD) were included in the study (n = 30; age range, 68-70 years). The results were compared to the healthy control groups. The enzyme-linked immunosorbent assay (ELISA) inhibition test for the determination of AGEs is based on a rabbit anti-AGE, affinity-purified antibody and a model AGE-myoglobin antigen, in which a serum sample treated with proteinase K is used as an inhibitor. For the measurement of immune complexes and anti-AGE antibodies, the corresponding ELISA tests have been applied. The AGE level in the VaD group (49.5 U_AGE) was higher than in AD patients (46.1 U_AGE). The level of total AGEs in the sera of AD patients was significantly lower than in the control group (50/51.6 U_AGE). These relations were not observed with regard to the immune complexes and anti-AGE antibody levels in AD (70.2 U_IC/0.027 U_IgG) and VaD (83 U_IC/0.034 U_IgG) patients because the levels of these parameters were similar to the controls (76.2 U_IC/0.042 U_IgG). The work revealed the lower level of circulating serum AGEs in patients with AD in relation to healthy controls.

Keywords

Alzheimer’s disease vascular dementia glycation products advanced glycation end products AGEs biological markers

References

Yim MB , Yim HS , Lee C , Kang SO , Chock PB. Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci. 2001;928: 48-53.

Fu MX , Wells-Knecht KJ , Blackledge JA , Lyons TJ , Thorpe SR , Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43: 676-683.

Shipanova IN , Glomb MA , Nagaraj RH. Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Arch Biochem Biophys. 1997;344: 29-36.

Al-Abed Y , Kapurniotu A , Bucala R. Advanced glycation end products: detection and reversal. Methods Enzymol. 1999;309: 152-171.

Nagai R , Hayashi CM , Xia L , Takeya M , Horiuchi S. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J Biol Chem. 2002;277: 48905-48912.

Horie K , Miyata T , Yasuda T , et al. Immunohistochemical localization of advanced glycation end products, pentosidine and carboxymethyllysine in lipofuscin pigments of Alzheimer’s disease and aged neurons. Biochem Biophys Res Commun. 1997;236: 327-332.

Loske C , Gerdemann A , Schepl W , et al. Transition metal-mediated glycoxidation accelerates cross-linking of B-amyloid peptide. Eur J Biochem. 2000;267: 4171-4178.

Smith MA , Taneda S , Richey PL , et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A. 1994;91: 5710-5714.

Sasaki N , Toki S , Chowei H , et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease. Brain Res. 2001;88: 256-262.

10.

Izuhara Y , Miyata T , Ueda Y , et al. A sensitive and specific ELISA for plasma pentosidine. Nephrol Dial Transplant. 1999;14: 576-580.

11.

McKhan G , Drachman D , Folstein M , Katzman R , Price D , Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34: 939-944.

12.

Roman GC , Tatemichi TK , Erkinjuntti T. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Work Group. Neurology. 1993;43: 250-260.

13.

Boratyński J , Roy R. High temperature conjugation of proteins with carbohydrates. Glycoconj J. 1998;15: 131-138.

14.

Ługowski C , Kułakowska M , Romanowska E. Characterization and diagnostic application of a lipopolysaccharide core oligosaccharide-protein conjugate. J Immunol Meth. 1986;95: 187-194.

15.

Turk Z , Ljubic S , Turk N , Benko B. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta. 2001;303: 105-115.

16.

Leszek J , Ferens-Sieczkowska M , Kątnik-Prastowska I. Fluorescent advanced glycation endproducts in sera of Alzheimer’s disease patients. Perspectives in Neurosciences. 2005;373-381.

17.

Ko L , Ko EC , Nacharaju P , et al. An immunochemical study on tau glycation in paired helical filaments. Brain Res. 1999;830: 301-313.

18.

Můnch G , Cunningham AM , Riederer P , Braak E. Advanced glycation endproducts are associated with Hirano bodies in Alzheimer’s disease. Brain Res. 1998;796: 307-310.

19.

Nagai R , Horiuchi S. Application of monoclonal antibody libraries for the measurement of glycation adducts. Biochem Soc Trans. 2003;31: 1438-1440.